Gaël Thomas

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Petra Pharma Corp. operates as a drug development company that develops novel small molecules for the treatment of cancer and metabolic diseases. The company was founded by Lewis Clayton Cantley and Nathanael S. Gray in 2016 and is headquartered in New York, NY.

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.

Aptalis Pharma, Inc. develops, manufactures, markets pharmaceutical products for cystic fibrosis and gastroenterology. The company's products include Zenpep, Canasa, Carafate, Pylera, Lacteal, Panzytrat, Delursan, Rectiv and Salofalk.. It provides therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. The company formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary pharmaceutical technology. Aptalis Pharma was founded 1982 and is headquartered in Birmingham, AL.

Deep Genomics, Inc. provides machine learning, genome biology and precision medicine. It develops an integrated computational system that could learn, predict, and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes. The firm offers SPIDEX database, which is a set of genetic variants and their predicted effects on human splicing across the entire genome. Its SPIDEX database covers all synonymous, missense, and nonsense exonic SNVs, as well as intronic SNVs that are up to 300nt from splice junctions. The company was founded by Brendan Frey and Hui Yuan Xiong in 2015 and is headquartered in Toronto, Canada.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Aptalis Pharma SAS is engaged in manufacturing pharmaceutical preparations. Its products include zenpep, canasa, carafate, pylera, rectiv, viokace, ultresa lacteol, delursan, panzytrat and salofalk. The company was founded in 1982 and is headquartered in Courbevoie, France.

Aptalis Holdings Inc. operates as a holding company that develops, manufactures, licenses, markets and distributes therapies for unmet medical needs. It includes cystic fibrosis and gastrointestinal disorders through its subsidiaries. It also formulates and clinically develops enhanced pharmaceutical, biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking and orally disintegration tablet formulations. The company was founded on January 10, 2008 and is headquartered in Bridgewater, NJ.

Aptalis Pharma US, Inc. markets pharmaceutical products and services for the treatment of gastrointestinal diseases and disorders. It offers pancrelipase capsules, ursodiol tablets, porfimer sodium for injections, shake mixes, calorie boosters, clearance devices and multivitamin supplements. The firm also provides products for active ulcerative, liver diseases, pancreatic diseases, cystic fibrosis, chronic obstructive pulmonary disease, HIV/AIDS and cancer. The company was founded in 1991 and is headquartered in Wilmington, DE.

Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999.

Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA.

Century Club of San Diego engages in the promotion of golf events to support San Diego community and local youth programs. The company was founded in July 1961 and is headquartered in La Jolla, CA.

Decoy Biosystems, Inc. provides cancer immunotherapy services. The company was founded on August 14, 2013 and is headquartered in San Diego, CA.

MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.

Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA.

Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA.

Shape Therapeutics, Inc. operates as a biotechnology firm. It offers genome medicine. The company was founded by Francois Vigneault and John D. Suliman in 2018 and is headquartered in Seattle, WA.

Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.